Page 76 - Read Online

Page 360 Neumann et al. J Transl Genet Genom 2022;6:353-60 https://dx.doi.org/10.20517/jtgg.2022.06

targeting chimeric molecule with CDK9 inhibitor. PLoS One 2020;15:e0232068. DOI PubMed PMC
20. Jung M, Kim S, Lee JK, et al. Clinicopathological and preclinical findings of NUT carcinoma: a multicenter study. Oncologist
2019;24:e740-8. DOI PubMed PMC
21. Zhao C, Dong H, Xu Q, Zhang Y. Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present). Expert Opin Ther
Pat 2020;30:263-74. DOI PubMed
22. Shiota H, Alekseyenko AA, Wang ZA, et al. Chemical screen identifies diverse and novel histone deacetylase inhibitors as repressors
of NUT function: implications for NUT carcinoma pathogenesis and treatment. Mol Cancer Res 2021;19:1818-30. DOI PubMed
PMC
23. French CA. Pathogenesis of NUT midline carcinoma. Annu Rev Pathol 2012;7:247-65. DOI PubMed
24. Napolitano M, Venturelli M, Molinaro E, Toss A. NUT midline carcinoma of the head and neck: current perspectives. Onco Targets
Ther 2019;12:3235-44. DOI PubMed PMC
25. Grayson AR, Walsh EM, Cameron MJ, et al. MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of
differentiation in NUT midline carcinoma. Oncogene 2013;33:1736-42. DOI PubMed PMC
26. Piha-Paul SA, Hann CL, French CA, et al. Phase 1 study of molibresib (GSK525762), a bromodomain and extra-terminal domain
protein inhibitor, in NUT carcinoma and other solid tumors. JNCI Cancer Spectr 2020;4:pkz093. DOI PubMed PMC
27. Lewin J, Soria JC, Stathis A, et al. Phase Ib trial with birabresib, a small-molecule inhibitor of bromodomain and extraterminal
proteins, in patients with selected advanced solid tumors. J Clin Oncol 2018;36:3007-14. DOI PubMed
28. Stathis A, Zucca E, Bekradda M, et al. Clinical response of carcinomas harboring the BRD4-NUT oncoprotein to the targeted
bromodomain inhibitor OTX015/MK-8628. Cancer Discov 2016;6:492-500. DOI PubMed PMC
29. Liao S, Maertens O, Cichowski K, Elledge SJ. Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers
a synergism between BETis and CDK4/6is. Genes Dev 2018;32:1188-200. DOI PubMed PMC
30. Hogg SJ, Vervoort SJ, Deswal S, et al. BET-bromodomain inhibitors engage the host immune system and regulate expression of the
immune checkpoint ligand PD-L1. Cell Rep 2017;18:2162-74. DOI PubMed PMC
31. Xie XH, Wang LQ, Qin YY, et al. Clinical features, treatment, and survival outcome of primary pulmonary NUT midline carcinoma.
Orphanet J Rare Dis 2020;15:183. DOI PubMed PMC